Results 171 to 180 of about 289,641 (264)

Integrated Clinical and Proteomic Profiling of CD19 CAR‐T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T‐cell therapy in patients with progressive systemic sclerosis. Methods Patients with progressive systemic sclerosis received CD19 CAR‐T cell therapy and were followed longitudinally for safety, clinical efficacy, immune ...
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

A machine learning-based method to optimize the immunogenicity of human leukocyte antigen class I-restricted neoantigens. [PDF]

Brief Bioinform
Zhang J, Zhou W, Yu J, Yan C, Liu J.
europepmc   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T‐Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

Arthritis &Rheumatology, Accepted Article.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T‐cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova, Jaspreet Kaur, Gabrielle Buckley, S.M. Mansour Haeryfar, Lisa Cameron, Ewa Cairns, Lillian Barra   +6 more
wiley   +1 more source

Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens. [PDF]

Explor Med
Georgopoulos AP, James LM.
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Major Human Leukocyte Antigen Expression in Respiratory Papillomatosis Clinical Specimens. [PDF]

Laryngoscope
Robbins Y, Lassoued W, Bai K, Huynh A, Norberg SM, Allen CT.   +5 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Association of Human Leukocyte Antigen Polymorphisms With Moderate-to-Severe Dry Eye With and Without Sjögren's Syndrome. [PDF]

Invest Ophthalmol Vis Sci
Chen Z, Jiang D, Zheng Q, Xing S, Li J, Lin L, Ren L, Xu H, Yu X, Tong L, Chen W.   +10 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Short Course Immunosuppression to Prevent Transfusion-Related Human Leukocyte Antigen Sensitization in Kidney Transplant Candidates: Commentary. [PDF]

Kidney360
Li JSY.
europepmc   +1 more source